I agree that many types of treatments have been advancing. Closed loop is a good example, and stem cell-based islet transplants are in real clinical trials now.

I agree that many types of treatments have been advancing. Closed loop is a good example, and stem cell-based islet transplants are in real clinical trials now. We have gotten synthetic insulins that act much faster like Fiasp and stuff like Tresiba that's a multi-day action time prolonged insulin. GLP1 inhibitors are more commonly available for T1Ds, especially now that they are in weight loss drugs that doctors are starting to more easily prescribe off-label to T1s. Metformin has basically become on-label for T1Ds due to its benefits to insulin sensitivity. But the smart insulin hasn't made much progress for the last several decades. I'm not saying it's all doom and gloom. I'm bringing attention to different rates these things evolve at and questioning why GRIs haven't left the lab since the 90s. :)